The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.

Robert I. Haddad,Douglas Adkins,Lisa Licitra,Justine Yang Bruce,Maura L. Gillison,Myung-Ju Ahn,Ching Yun Hsieh,Hung-Ming Wang,Amanda Psyrri,Jean-Pascal Machiels,Binaifer Balsara,Mollie Leoni,Kevin J. Harrington,Nabil F. Saba,Alan Loh Ho

The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.

2021

Robert I. Haddad
Douglas Adkins
Lisa Licitra
Justine Yang Bruce
Maura L. Gillison
Myung-Ju Ahn
Ching Yun Hsieh
Hung-Ming Wang
Amanda Psyrri
Jean-Pascal Machiels
Binaifer Balsara
Mollie Leoni
Kevin J. Harrington
Nabil F. Saba
Alan Loh Ho

TPS6087Background: Head and neck squamous cell carcinoma (HNSCC) accounts for more than 830,000 new cancer cases each year worldwide. The prognosis for recurrent and/or metastatic (R/M) HNSCC patie...

Keywords:

Medicine
Internal medicine
Oncology
in patient
Tipifarnib
HRAS
Cancer
Head and neck squamous-cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations